<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">  <head>    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>    <title>All Interactions with Raltegravir</title><link rel="stylesheet" href="css/insite.css" type="text/css"/><link rel="stylesheet" href="css/layout.css" type="text/css"/><link rel="stylesheet" href="css/topNav.css" type="text/css"/><!-- jquery javascript --><script type="text/javascript" src="script/jquery/load.js"><!--  --></script><script type="text/javascript" src="app-js/jquery.scrollTo.js"> </script><script type="text/javascript" src="app-js/jquery.cycle.js"> </script><script type="text/javascript" language="JavaScript">
        function openWindow(url,name){
            newWin = window.open(url,name,'status,toolbar,menubar,resizable,scrollbars,left=20,top=20,width=650,height=600')
            newWin.focus()
        }

        function openXWindow(url,name){
            newXWin = window.open(url,name)
            newXWin.focus()
        }

		/* BASED ON NEC DEMO.XML */
		   // REVEAL HIDDEN LOGIC QUESTION
				function branchNext (event) {
					$.log("BRANCHNEXT() :  enter");
					var n = $(this).children("input:checked").size();

					if (n)   {
						 var reveal = "." + $($(this).children("input:checked")).attr("name") + "-" + $($(this).children("input:checked")).val();

						 $(reveal).removeClass("hidden").addClass("question-revealed");
					}
			   }

		// HIDE TO-BE-REVEALED LOGIC QUESTIONS
			$(document).ready(function() { hideLogicQuestions($(document).children()[0]) });

			function hideLogicQuestions (element) {
				$.log("hideLogicQuestions() : enter");
				$(".hidden-question").each(function() {
					$(this).addClass("hidden").removeClass("question-revealed");
				});
		   }
		/* END FROM NEC DEMO.XML */


			function expand(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				/* CLOSE ALL SECTIONS AND RESET BUTTONS
				$(".expandable", section).addClass("hidden");
				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
				$(".expandAll", section).removeClass("hidden");
				$(".collapseAll", section).addClass("hidden");
				*/

				// OPEN SPECIFIED SECTION AND UPDATE ITS BUTTONS
				section.removeClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");

				// $(this).siblings(".expandAll").addClass("hidden");
				// $(this).siblings(".collapseAll").removeClass("hidden");
			}
			function collapse(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");

				$(this).siblings(".collapseAll").addClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");
			}

			function expandAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.removeClass("hidden");
				$(".expandable", section).removeClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".expand").addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");
				$(this).siblings(".collapseAll").removeClass("hidden");

				$(".expand", section).addClass("hidden");
				$(".collapse", section).removeClass("hidden");
			}
			function collapseAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(".expandable", section).addClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".collapse").addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");

				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
			}


			// connect the correct fuctions
			function sconnect(element) {
				$(".reveal-question", element).click(branchNext);

				$(".expand", element).click(expand);
				$(".expandAll", element).click(expandAll);
				$(".collapse", element).click(collapse);
				$(".collapseAll", element).click(collapseAll);
			}

			// load method for adding connections
			$(document).ready(function() {
				sconnect($(document).children()[0])
			 });

			 $(document).ready(function(){
			 $('.carousel ul').cycle({'prev':'.previous','next':'.next','play':'.play','pause':'.pause'});
			 $(".carousel-hidden").each(function () {
			 $(this).removeClass("carousel-hidden");
			 });
			 });


		</script><!--*********************************************************
    *************************************************************
    REPLACE GOOGLE ANALYTICS SCRIPT BEFORE PUBLISHING TO LIVESITE
    You can find the script in google-analytics.js **************
    *************************************************************
    **********************************************************--><script type="text/javascript">
   
     var _gaq = _gaq || [];
     _gaq.push(['_setAccount', 'UA-19627862-1']);
     _gaq.push(['_trackPageview']);
   
     (function() {
       var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
       ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
       var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
     })();
   
</script></head><body><div class="floatpage"><div id="ucsf"><a href="http://ucsf.edu/"><img src="images/masthead/ucsf.gif" alt="University of California, San Francisco Logo"/></a><p>University of California, San Francisco | <a href="http://www.ucsf.edu/about-ucsf/">About UCSF</a> | <a href="http://www.ucsf.edu/ucsf/search">Search UCSF</a> | <a href="http://www.ucsfhealth.org/">UCSF Medical Center</a></p></div><div id="header"><div style="float:left;"><a href="InSite" style="display:block;"><img src="images/masthead/splash-logo-top.gif" alt="HIV InSite"/></a><h1 class="site-description" style="clear:both; width: 475px;">Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco</h1></div><div class="site-sub-navigation"><a href="InSite">Home</a> | <a href="InSite?page=pb-00-00">Patient/Public</a> | <a href="InSite?page=Audio">Audio</a> | <a href="InSite?page=News">News</a> | <a href="InSite?page=Links">Links</a></div><div class="sitesearch"><form action="search" method="get" id="search"><input type="hidden" name="page" value="sr-00-00"/><input type="hidden" name="post" value="1"/><label for="SearchEntry">Search</label><input type="text" size="28" name="SearchEntry" id="SearchEntry" aria-label="Search"/><input type="submit" id="I1" value="Search" style="margin-left: 5px;"/></form></div><div id="site-navigation"><ul><li class="site-navigation"><a href="InSite?page=KB">Knowledge Base</a></li><li class="site-navigation"><a href="InSite?page=Treatment">Treatment</a></li><li class="site-navigation"><a href="InSite?page=Prevention">Prevention</a></li><li class="site-navigation"><a href="InSite?page=Policy">Policy Analysis</a></li><li class="site-navigation"><a href="InSite?page=cr-00-00">Global Response</a></li></ul></div></div><div id="content-target"><div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="right"><font face="Arial, Helvetica" size="-2"><a href="http://hivinsite.ucsf.edu/InSite">Home</a> &gt; <a href="http://hivinsite.ucsf.edu/InSite?page=Treatment">Treatment</a> &gt; <a href="InSite?page=ar-00-02">Interactions</a></font></td></tr><tr><td><img alt="" src="images/transparent.gif" border="0" height="10" width="1"/></td></tr></tbody></table><div class="pgtitle">Database of Antiretroviral Drug Interactions</div><img alt="" src="images/greyline.gif"/><br/><p style="margin-top:0;padding-top:0;" class="kbrsec1">All Interactions with Raltegravir (Isentress)</p><table class="datatable" width="100%"><thead><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr></thead><tr><td valign="top" width="10%">Antacids<sup><a href="#525">525</a></sup><div>(Maalox, Mylanta, Riopan, Milk of Magnesia, others)</div></td><td valign="top">Maalox Extra Strength</td><td valign="top">400 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: no significant change; Cmax: increased 53%; Cmin: decreased 65%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#461">461</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg BID</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">RAL AUC: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup><a href="#428">428</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg BID on days 6-12 and days 13-26</td><td valign="top">400 mg BID on days 1-5 and days 13-26</td><td valign="top">Atazanavir AUC: decreased 17%; Cmin: decreased 29% (compared to atazanavir BID)</td><td valign="top">Raltegravir AUC: increased 54%; Cmin: increased 48%; Cmax: increased 39%</td><td valign="top">Possibly increased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#3">3</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg with 100 mg ritonavir QD</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: increased 41%; Cmax: increased 24%; Cmin: increased 77%</td><td valign="top">Possibly increased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup><a href="#3">3</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD</td><td valign="top">100 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: increased 72%; Cmax: increased 53%; Cmin: increased 95%</td><td valign="top">Possibly increased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Boceprevir<sup><a href="#585">585</a></sup><div>(Victrelis)</div></td><td valign="top">800 mg TID</td><td valign="top">400 mg x 1</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Buprenorphine<sup><a href="#575">575</a></sup><div>(Suboxone)(Buprenex)</div></td><td valign="top">stable dose for at least 3 weeks</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Darunavir<sup><a href="#416">416</a></sup><div>(DRV)(Prezista)</div></td><td valign="top">600 mg Q12H with 100 mg ritonavir Q12H</td><td valign="top">400 mg Q12H</td><td valign="top">- </td><td valign="top">Raltegravir AUC: decreased 29%; Cmin: increased 38%; Cmax: decreased 33%</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir<sup><a href="#695">695</a></sup><div>(Viekira)</div></td><td valign="top">paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg twice daily</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC increased 134%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Efavirenz<sup><a href="#3">3</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">600 mg QD</td><td valign="top">400 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 36%; Cmax: 36%; Cmin: decreased 21%</td><td valign="top">Possibly decreased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Efavirenz<sup><a href="#436">436</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">600 mg x 14 d</td><td valign="top">400 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 36%; Cmin: decreased 21%; Cmax: decreased 36%</td><td valign="top">-</td><td valign="top">Induction of UGT1A1 by efavirenz</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Elbasvir/grazoprevir<sup><a href="#733">733</a>, <a href="#727">727</a></sup><div>(Zepatier)</div></td><td valign="top">Elbasvir 50mg QD with grazoprevir 100 mg QD</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Increase RAL AUC 43% with grazoprevir</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dosage adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Etravirine<sup><a href="#405">405</a></sup><div>(ETR)(Intelence)</div></td><td valign="top">-</td><td valign="top">400 mg BID</td><td valign="top">Etravirine Cmin: increased 17%</td><td valign="top">Raltegravir Cmin: decreased 34%</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Etravirine<sup><a href="#433">433</a></sup><div>(ETR)(Intelence)</div></td><td valign="top">200 mg BID</td><td valign="top">400 mg BID</td><td valign="top">Etravirine Cmin: increased 17%</td><td valign="top">Raltegravir Cmin: decreased 34%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Famotidine<sup><a href="#445">445</a></sup><div>(Pepcid)</div></td><td valign="top">20 mg QD given 2 hours before raltegravir</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: increased 45%; Cmax: increased 60%</td><td valign="top">-</td><td valign="top">Possibly due to increased bioavailability due to increased gastric pH</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fosamprenavir<sup><a href="#440">440</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">1400 mg BID</td><td valign="top">400 mg BID</td><td valign="top">Amprenavir AUC: decreased 19%; Cmax: decreased 17%; Cmin: decreased 33%</td><td valign="top">Raltegravir AUC: decreased 29%; Cmin: decreased 68%</td><td valign="top">-</td><td valign="top">Possible induction of p-gp</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Fosamprenavir<sup><a href="#440">440</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">1400 mg QD with 100 mg ritonavir QD</td><td valign="top">400 mg BID</td><td valign="top">Amprenavir Cmax: increased 27%; Cmin: decreased 17%</td><td valign="top">Raltegravir AUC: decreased 30%; Cmax: decreased 14%; Cmin: decreased 41%</td><td valign="top">-</td><td valign="top">Possible induction of p-gp</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fosamprenavir<sup><a href="#440">440</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">700 mg fosamprenavir BID with 100 mg ritonavir BID</td><td valign="top">400 mg BID</td><td valign="top">Amprenavir AUC: decreased 25%; Cmin: decreased 33%; Cmax: decreased 25%</td><td valign="top">Raltegravir AUC: decreased 54%; Cmax: decreased 36%; Cmin: decreased 54%</td><td valign="top">-</td><td valign="top">Possible induction of p-gp</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ginkgo biloba<sup><a href="#619">619</a></sup><div/></td><td valign="top">120 mg BID</td><td valign="top">400 mg x 1</td><td valign="top">Ginkgo biloba AUC: increased 21%; Cmax: increased 44%</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">Potential increase in raltegravir bioavailability</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Lamotrigine<sup><a href="#437">437</a></sup><div>(Lamictal)(Lamictal)</div></td><td valign="top">100 mg</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#413">413</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">400 mg/100 mg BID</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">Raltegravir Cmin: decreased 30%</td><td valign="top">-</td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Maraviroc<sup><a href="#535">535</a></sup><div>(MVC)(Selzentry)</div></td><td valign="top">300 mg Q12H</td><td valign="top">400 mg Q12H</td><td valign="top">Maraviroc Cmin: decreased 21%; Cmax: decreased 20%</td><td valign="top">Raltegravir AUC: decreased 37%; Cmin: decreased 28%; Cmax: decreased 33%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Midazolam<sup><a href="#408">408</a></sup><div>(Versed)(Versed)</div></td><td valign="top">2 mg x 1</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Omeprazole<sup><a href="#445">445</a></sup><div>(Prilosec)(Prilosec)</div></td><td valign="top">20 mg QD</td><td valign="top">400 mg BID</td><td valign="top">- </td><td valign="top">Raltegravir AUC: increased 39%; Cmax: increased 50%; Cmin: increased 24%</td><td valign="top">- </td><td valign="top">Possibly due to increased bioavailability due to increased gastric pH</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Omeprazole<sup><a href="#444">444</a>, <a href="#419">419</a></sup><div>(Prilosec)(Prilosec)</div></td><td valign="top">20 mg QD x 4 days</td><td valign="top">400 mg Q12H</td><td valign="top">- </td><td valign="top">Raltegravir AUC: increased 212%; Cmin: increased 46%; Cmax: increased 315%</td><td valign="top">- </td><td valign="top">Possibly due to increased bioavailability due to increased gastric pH</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Pravastatin<sup><a href="#457">457</a></sup><div>(Pravachol)(Pravachol)</div></td><td valign="top">40 mg QD</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">Raltegravir AUC: no significant change; Cmax: increased 31%; Cmin: decreased 41%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Pravastatin<sup><a href="#465">465</a></sup><div>(Pravachol)(Pravachol)</div></td><td valign="top">40 mg QD</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">Raltegravir Cmax: increased 31%; Cmin: decreased 41%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifabutin<sup><a href="#432">432</a></sup><div>(Mycobutin)(Mycobutin)</div></td><td valign="top">300 mg QD x 14 d</td><td valign="top">400 mg BID</td><td valign="top">- </td><td valign="top">Raltegravir AUC: increased 19%; Cmax: increased 39%; Cmin: decreased 20%</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Rifampin<sup><a href="#436">436</a>, <a href="#3">3</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">400 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 40%; Cmax: decreased 38%; Cmin: decreased 61%</td><td valign="top">Possibly decreased raltegravir effects</td><td valign="top">Induction of UGT 1A1</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Possibly rifabutin</b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#418">418</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">800 mg Q12H</td><td valign="top">- </td><td valign="top">Raltegravir AUC: increased 27%; Cmin: decreased 53%; Cmax: increased 62% (compared to 400 mg raltegravir Q12H when given alone)</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>Use caution if this combination must be used</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr><td valign="top" width="10%">Rifampin<sup><a href="#438">438</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">400 mg QD x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 40%; Cmin: decreased 61%; Cmax: decreased 38%</td><td valign="top">Decreased raltegravir effects</td><td valign="top">Induction of UGT1A1 by rifampin</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#3">3</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">800 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: increased 27%; Cmax: increased 62%; Cmin: decreased 53% (all compared to raltegravir 400 mg BID)</td><td valign="top">-</td><td valign="top">Induction of UGT1A1 by rifampin</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr><td valign="top" width="10%">Rifapentine<sup><a href="#693">693</a></sup><div>(Priftin)(Priftin)</div></td><td valign="top">900 mg once weekly for 3 weeks or 600 mg once daily for 10 scheduled doses (days 1, 4–8 and 11–14)</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">When given with rifapentine once weekly for 3 weeks raltegravir AUC increased 79%, Cmax increased 89% and Cmin decreased 12%.  When given with rifapentine for 10 daily doses, Cmin decreased 41%
</td><td valign="top"> Potential for increased raltegravir adverse effects if given with rifapentine once weekly; potential for decreased raltegravir effectiveness if rifapentine co-administered daily</td><td valign="top">-</td><td valign="top"><p>Avoid co-administration</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifapentine<sup><a href="#589">589</a></sup><div>(Priftin)</div></td><td valign="top">900 mg PO once weekly</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: increased 73%; Cmax: increased 89%; Cmin: decreased 44%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Rilpivirine<sup><a href="#591">591</a></sup><div>(RPV)(Edurant)</div></td><td valign="top">25 mg QD</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir Cmin: increased 27%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Raltegravir</th><th>Effect on Drug Levels</th><th>Effect on Raltegravir Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ritonavir<sup><a href="#3">3</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">100 mg BID</td><td valign="top">400 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 16%; Cmax: decreased 24%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ritonavir<sup><a href="#436">436</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">100 mg BID x 16 d</td><td valign="top">400 mg x 1</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 16%;  Cmax: decreased 24%</td><td valign="top">- </td><td valign="top">Induction of UGT1A1 by ritonavir</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Simeprevir<sup><a href="#727">727</a>, <a href="#673">673</a></sup><div>(Olysio)</div></td><td valign="top">150 mg QD x 7 days</td><td valign="top">400 mg BID x 7 days</td><td valign="top">Simeprevir AUC decreased 11%; Cmin decreased 14%</td><td valign="top">Raltegravir Cmin: increased 14%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Sofosbuvir<sup><a href="#659">659</a></sup><div>(Sovaldi)</div></td><td valign="top">400 mg x 1</td><td valign="top">400 mg QD</td><td valign="top">Sofosbuvir Cmax decreased 43%; AUC: decreased 27%</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Sofosbuvir/velpatasvir<sup><a href="#751">751</a></sup><div>(Epclusa)</div></td><td valign="top">400 mg/100 mg</td><td valign="top">400 mg twice daily</td><td valign="top">-</td><td valign="top"> Raltegravir Cmin increased 8%; AUC increased 5%.</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p> No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Telaprevir<sup><a href="#637">637</a></sup><div>(Incivek)</div></td><td valign="top">750 mg Q8H</td><td valign="top">400 mg BID</td><td valign="top">No significant change</td><td valign="top">Raltegravir AUC: increased 31%; Cmax: increased 26%; Cmin: increased 78%</td><td valign="top">Possibly increased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary </p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#3">3</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: increased 49%; Cmax: increased 64%</td><td valign="top">Possibly increased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#3">3</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">500 mg BID with 200 mg ritonavir BID</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 24%; Cmax: decreased 18%; Cmin: decreased 55%</td><td valign="top">Possibly decreased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#439">439</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">500/200 mg BID</td><td valign="top">400 mg BID</td><td valign="top">-</td><td valign="top">Raltegravir AUC: decreased 24%; Cmin: decreased 55%</td><td valign="top">Induction of UGT1A1 by tipranavir/ritonavir</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#bbbbbb"><td class="cellleft" colspan="8">"-" indicates that there are no data available
                
            </td></tr></table><table cellspacing="2" cellpadding="0" border="0"><tr><td valign="top" class="cellrightblue"><a name="3"> </a>3:</td><td class="cellleft">Isentress [package insert]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; October 2007.</td></tr><tr><td valign="top" class="cellrightblue"><a name="405"> </a>405:</td><td class="cellleft">Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; 2010.</td></tr><tr><td valign="top" class="cellrightblue"><a name="408"> </a>408:</td><td class="cellleft">Iwamoto M, Wenning, LA, Troyer MD, et al. lack of a pharmacokinetic interaction of MK-0518 on midazolam [abstract P300]. 8th International Congress on Drug Therapy in HIV Infection. 2006 12-16 November; Glasgow, Scotland.</td></tr><tr><td valign="top" class="cellrightblue"><a name="413"> </a>413:</td><td class="cellleft">Rhame F, Long M, Acosta A. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults [TuPE0075]. 17th International AIDS Conference, August 3-8, 2008; Mexico City, Mexico.</td></tr><tr><td valign="top" class="cellrightblue"><a name="416"> </a>416:</td><td class="cellleft">Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic evaluation of darunavir/ritonavir and raltegravir in healthy subjects [poster A-962]. 48th ICAAC/IDS Annual Meeting; October 25-28, 2008; Washington, D.C.</td></tr><tr><td valign="top" class="cellrightblue"><a name="418"> </a>418:</td><td class="cellleft">Brainard DM, Petry A, Hanley WD, et al. Doubling the dose of raltegravir does not increase trough levels in the presence of rifampin [abstract A-964]. 48th ICAAC/IDSA Annual Meeting 2008; October 25-28; Washington, D.C.</td></tr><tr><td valign="top" class="cellrightblue"><a name="419"> </a>419:</td><td class="cellleft">Iwamoto M, Wenning LA, Nguyen B-Y, et al. Omeprazole increases plasma levels of raltegravir in healthy subjects [abstract A-963]. 48th ICAAC/IDSA Annual Meeting 2008; October 25-28; Washington, D.C.</td></tr><tr><td valign="top" class="cellrightblue"><a name="428"> </a>428:</td><td class="cellleft">Zhu L, Mahnke L, Butterton J, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy subjects [poster 696]. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada.</td></tr><tr><td valign="top" class="cellrightblue"><a name="432"> </a>432:</td><td class="cellleft">Brainard DM, Petry AS, Fang L, et al. Lack of a clinically important effect of rifabutin on raltegravir pharmacokinetics [abstract A1-1296]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="433"> </a>433:</td><td class="cellleft">Anderson MS, Kakuda TM, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegavir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228-32.</td></tr><tr><td valign="top" class="cellrightblue"><a name="436"> </a>436:</td><td class="cellleft">Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008; 52: 4338-4343.</td></tr><tr><td valign="top" class="cellrightblue"><a name="437"> </a>437:</td><td class="cellleft">Van Luin M, Colbers A, Verwey-van Wissen C, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol 2009; 49: 1220-27.</td></tr><tr><td valign="top" class="cellrightblue"><a name="438"> </a>438:</td><td class="cellleft">Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2852-56.</td></tr><tr><td valign="top" class="cellrightblue"><a name="439"> </a>439:</td><td class="cellleft">Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2752-55.</td></tr><tr><td valign="top" class="cellrightblue"><a name="440"> </a>440:</td><td class="cellleft">Luber A, Slowinski PD, Acosta E, et al. Steady-state pharmacokinetics of fosamprenavir and raltegravir alone and combined with unboosted and ritonavir-boosted fosamprenavir [abstract A1-1297]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="444"> </a>444:</td><td class="cellleft">Iwamoto M, Wenning LA, Nguyen B-Y, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48: 489-92.</td></tr><tr><td valign="top" class="cellrightblue"><a name="445"> </a>445:</td><td class="cellleft">Rhame F, Matson M, Wood D, et al. Effects of famotidine and omeprazole on raltegravir pharmacokinetics in HIV-infected persons [abstract 4.1]. 12th European AIDS Conference, November 11-14, 2009; Cologne, Germany.</td></tr><tr><td valign="top" class="cellrightblue"><a name="457"> </a>457:</td><td class="cellleft">Van Luin M, Colbers EPH, Verwey-van Wissen CPWGM, et al. Drug-drug interactions between raltegravir and pravastain in healthy volunteers poster 29]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9, 2010; Sorrento, Italy.</td></tr><tr><td valign="top" class="cellrightblue"><a name="461"> </a>461:</td><td class="cellleft">Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of unboosted atazanavir on the pharmacokinetics of raltegravir in HIV-1 infected patients [abst. 49]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 2010 April 7-9; Sorrento, Italy.</td></tr><tr><td valign="top" class="cellrightblue"><a name="465"> </a>465:</td><td class="cellleft">Van Luin M, Colbers A, Van Ewijk-Beneken Kolmer EW, et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr 2010; April 15.</td></tr><tr><td valign="top" class="cellrightblue"><a name="525"> </a>525:</td><td class="cellleft">Bumpass B, Brundage R, Meditz A, et al. Effect of antacids on the pharmacokinetics of raltegravir in HIV seronegative volunteers [abstract A1-2013]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 September 12-15; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="535"> </a>535:</td><td class="cellleft">Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Brit J Clin Pharmacol 2010; 69: 51-7.</td></tr><tr><td valign="top" class="cellrightblue"><a name="575"> </a>575:</td><td class="cellleft">Bruce RD, Moody K, Chodkowski D, et al. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir [MOPE176]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July, 2011; Rome, Italy.</td></tr><tr><td valign="top" class="cellrightblue"><a name="585"> </a>585:</td><td class="cellleft">de Kanter C, Blonk M, Colbers, A, et al. The influence of the HCV protease inhibitor bocepravir on the pharmacokinetics of the HIV integrase inhibitor raltegravir [paper #772LB]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012; Seattle, WA.</td></tr><tr><td valign="top" class="cellrightblue"><a name="589"> </a>589:</td><td class="cellleft">Weiner M, Peloquin C, Engle M, et al. The pharmacokinetic interaction between raltegravir and rifapentine in healthy volunteers [paper #615]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012. Seattle, WA.</td></tr><tr><td valign="top" class="cellrightblue"><a name="591"> </a>591:</td><td class="cellleft">Crauwels H, Stevens M, De La Rosa G, et al. Absence of pharmacokinetic interaction between the NNRTI rilpvirine and the integrase inhibitor raltegravir [paper# 617]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012. Seattle, WA.</td></tr><tr><td valign="top" class="cellrightblue"><a name="619"> </a>619:</td><td class="cellleft">Blonk M, Colbers A, Poirters A, Schouwenberg B, Burger D. Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers. Antimicrob Agents Chemother 2012; July 16. [Epub ahead of print].</td></tr><tr><td valign="top" class="cellrightblue"><a name="637"> </a>637:</td><td class="cellleft">Van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [abstract #36]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 17-20, 2011; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="659"> </a>659:</td><td class="cellleft">Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2013.</td></tr><tr><td valign="top" class="cellrightblue"><a name="673"> </a>673:</td><td class="cellleft">Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.</td></tr><tr><td valign="top" class="cellrightblue"><a name="693"> </a>693:</td><td class="cellleft">Weiner M, et. al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.  J. Antimicrob. Chemother. (2014) 69 (4): 1079-1085</td></tr><tr><td valign="top" class="cellrightblue"><a name="695"> </a>695:</td><td class="cellleft">Khatri A, Wang T, Wang H, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. 5-9 September 2014</td></tr><tr><td valign="top" class="cellrightblue"><a name="727"> </a>727:</td><td class="cellleft">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.</td></tr><tr><td valign="top" class="cellrightblue"><a name="733"> </a>733:</td><td class="cellleft">Unique Patient Populations: Patients with HIV/HCV Co-infection. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases. Available at http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection</td></tr><tr><td valign="top" class="cellrightblue"><a name="751"> </a>751:</td><td class="cellleft">Epclusa [package insert]. Foster City, CA: Gilead Sciences, 2016.</td></tr></table></div></div><div class="footer"><p class="footerlinks"><a href="InSite?page=About">About</a> | <a href="InSite?page=SM">Site Map</a> | <a href="fb?page=Feedback">Feedback</a> | <a href="InSite?page=Subscribe">Subscribe</a> | <a href="InSite?page=Donate">Donate</a> | <a href="InSite?page=Disclaimer">Disclaimer</a></p><p class="copyright"><a href="http://chi.ucsf.edu/" target="OffSite"><img src="images/footer/chi.gif" alt="UCSF - Center for HIV Information"/></a> HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.</p></div></div></body></html>